

# David E Cohn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3849701/publications.pdf>

Version: 2024-02-01

280  
papers

15,142  
citations

17440

63  
h-index

22829

112  
g-index

284  
all docs

284  
docs citations

284  
times ranked

15183  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 64-84.	4.9	700
2	The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology, 2009, 112, 55-59.	1.4	597
3	Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 4649-4655.	1.6	576
4	Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2006, 66, 7810-7817.	0.9	564
5	Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 170-199.	4.9	488
6	Outcome of Reproductive Age Women with Stage IA or IC Invasive Epithelial Ovarian Cancer Treated with Fertility-Sparing Therapy. Gynecologic Oncology, 2002, 87, 1-7.	1.4	257
7	A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage Iâ€“IV carcinosarcoma (CS) of the uterusâ€“†. Gynecologic Oncology, 2007, 107, 177-185.	1.4	257
8	Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 395-404.	4.9	250
9	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
10	Minimally invasive comprehensive surgical staging for endometrial cancer: Robotics or laparoscopy?. Gynecologic Oncology, 2009, 113, 36-41.	1.4	242
11	Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. Journal of Clinical Oncology, 2006, 24, 4324-4332.	1.6	239
12	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. New England Journal of Medicine, 2019, 381, 1929-1939.	27.0	217
13	HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients. Journal of Clinical Oncology, 2006, 24, 2376-2385.	1.6	216
14	Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene, 2018, 37, 3806-3821.	5.9	215
15	NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 660-666.	4.9	189
16	A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecologic Oncology, 2007, 105, 630-634.	1.4	187
17	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecologic Oncology, 2013, 129, 277-284.	1.4	185
18	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2019, 37, 1380-1390.	1.6	178

#	ARTICLE	IF	CITATIONS
19	Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 69-75.	1.6	165
20	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4301-4308.	1.6	163
21	Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer. <i>Gynecologic Oncology</i> , 2002, 85, 179-184.	1.4	162
22	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2841-2847.	1.6	159
23	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	1.6	155
24	At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 1247-1251.	1.6	152
25	Surgical Staging for Patients Presenting With Grade 1 Endometrial Carcinoma. <i>Obstetrics and Gynecology</i> , 2005, 105, 487-493.	2.4	144
26	A detailed analysis of the learning curve: Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 162-167.	1.4	144
27	Polymerase $\epsilon$ ( <i>POLE</i> ) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. <i>Cancer</i> , 2015, 121, 386-394.	4.1	142
28	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3062-3068.	1.6	141
29	Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013, 129, 22-27.	1.4	140
30	SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance. <i>Gynecologic Oncology</i> , 2010, 119, 7-17.	1.4	139
31	Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 92-120.	4.9	136
32	Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. <i>Gynecologic Oncology</i> , 2003, 91, 470-475.	1.4	131
33	Comprehensive Surgical Staging for Endometrial Cancer in Obese Patients. <i>Obstetrics and Gynecology</i> , 2009, 114, 16-21.	2.4	129
34	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5564-5572.	7.0	120
35	Robotic Hysterectomy and Pelvic Aortic Lymphadenectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2008, 112, 1207-1213.	2.4	116
36	Should the Presence of Lymphovascular Space Involvement Be Used to Assign Patients to Adjuvant Therapy Following Hysterectomy for Unstaged Endometrial Cancer?. <i>Gynecologic Oncology</i> , 2002, 87, 243-246.	1.4	113

#	ARTICLE	IF	CITATIONS
37	Uterine Neoplasms, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 248-280.	4.9	113
38	Bokhman Redux: Endometrial cancer "œtypes" in the 21st century. Gynecologic Oncology, 2017, 144, 243-249.	1.4	113
39	NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 888-895.	4.9	113
40	A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecologic Oncology, 2009, 114, 442-447.	1.4	111
41	Use of Complementary and Alternative Medicine among Women with Gynecologic Cancers. Gynecologic Oncology, 2002, 84, 363-367.	1.4	102
42	Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2014, 32, 458-464.	1.6	102
43	Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene, 2017, 36, 168-181.	5.9	99
44	Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecologic Oncology, 2009, 114, 128-134.	1.4	97
45	Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: A multi-site study performed at high volume cancer centers. Gynecologic Oncology, 2012, 126, 180-185.	1.4	97
46	A multi-institutional cohort study of adjuvant therapy in stage "II uterine carcinosarcoma. Gynecologic Oncology, 2012, 127, 22-26.	1.4	94
47	Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecologic Oncology, 2006, 102, 134-139.	1.4	91
48	Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2007, 67, 9603-9603.	0.9	88
49	Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecologic Oncology, 2004, 95, 588-592.	1.4	87
50	Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates. Cancer Research, 2007, 67, 7113-7123.	0.9	87
51	GM-CSF Induces Expression of Soluble VEGF Receptor-1 from Human Monocytes and Inhibits Angiogenesis in Mice. Immunity, 2004, 21, 831-842.	14.3	86
52	Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1374-1391.	4.9	86
53	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology, 2018, 148, 174-180.	1.4	83
54	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R33.	5.0	78

#	ARTICLE	IF	CITATIONS
55	Comprehensive miRNA profiling of surgically staged endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 656.e1-656.e8.	1.3	77
56	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	1.4	77
57	High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. <i>International Journal of Cancer</i> , 2017, 140, 555-564.	5.1	77
58	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 312-317.	1.4	75
59	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	1.4	73
60	A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 3503-3513.	0.9	72
61	HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 2316-2327.	0.9	71
62	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 486-490.	1.4	68
63	Inhibition of miR-328 <sup>3p</sup> Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 2314-2326.	0.9	68
64	The biological significance and clinical applications of exosomes in ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 199-205.	1.4	66
65	Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. <i>Gynecologic Oncology</i> , 2012, 125, 546-551.	1.4	64
66	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. <i>Obstetrics and Gynecology</i> , 2009, 114, 530-536.	2.4	62
67	A randomized phase III trial of IV carboplatin and paclitaxel $\times$ 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2011, 122, 89-94.	1.4	62
68	Lymphadenectomy for endometrial cancer: The controversy. <i>Gynecologic Oncology</i> , 2010, 117, 6-8.	1.4	61
69	Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. <i>Gynecologic Oncology</i> , 2012, 124, 36-41.	1.4	61
70	Uterine Sarcoma, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1321-1331.	4.9	58
71	Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 60.e1-60.e7.	1.3	58
72	Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2006, 108, 1208-1215.	2.4	56

#	ARTICLE	IF	CITATIONS
73	Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: Tissue microarray analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1262-1271.	1.3	55
74	Clinical and Pathologic Correlates in Surgical Stage II Endometrial Carcinoma. <i>Obstetrics and Gynecology</i> , 2007, 109, 1062-1067.	2.4	55
75	Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. <i>Cancer Prevention Research</i> , 2011, 4, 1401-1408.	1.5	53
76	Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2005, 96, 103-107.	1.4	52
77	Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 111, 461-466.	1.4	52
78	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin <sup>®</sup> ) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 477-483.	1.4	50
79	Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). <i>Gynecologic Oncology</i> , 2019, 153, 496-499.	1.4	50
80	Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. <i>Quality of Life Research</i> , 2007, 16, 89-100.	3.1	49
81	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 269-272.	1.4	49
82	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. <i>Modern Pathology</i> , 2012, 25, 1333-1344.	5.5	48
83	Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. <i>Gynecologic Oncology</i> , 2010, 117, 234-238.	1.4	46
84	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. <i>Gynecologic Oncology</i> , 2017, 147, 110-114.	1.4	46
85	A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?. <i>Gynecologic Oncology</i> , 2004, 95, 70-76.	1.4	45
86	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>JAMA Oncology</i> , 2016, 2, 1427.	7.1	45
87	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology</i> , 2017, 146, 373-379.	1.4	45
88	The role of MRI in the conservative management of endometrial cancer. <i>Gynecologic Oncology</i> , 2004, 93, 233-237.	1.4	44
89	Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. <i>Gynecologic Oncology</i> , 2013, 128, 309-315.	1.4	44
90	The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion. <i>American Journal of Surgical Pathology</i> , 2017, 41, 49-55.	3.7	44

#	ARTICLE	IF	CITATIONS
91	A black raspberry extract inhibits proliferation and regulates apoptosis in cervical cancer cells. <i>Gynecologic Oncology</i> , 2011, 123, 401-406.	1.4	43
92	Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 110, 152-157.	1.4	42
93	Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. <i>Cancer</i> , 2013, 119, 3653-3661.	4.1	42
94	Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2002, 85, 507-510.	1.4	41
95	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. <i>Gynecologic Oncology</i> , 2011, 123, 532-536.	1.4	40
96	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. <i>Genetics in Medicine</i> , 2012, 14, 670-680.	2.4	40
97	Robotic Trocar Site Small Bowel Evisceration After Gynecologic Cancer Surgery. <i>Obstetrics and Gynecology</i> , 2008, 112, 462-464.	2.4	39
98	HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 766-775.	3.4	39
99	HDAC10 as a potential therapeutic target in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 613-620.	1.4	39
100	Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 933-938.	2.5	38
101	Intraperitoneal spread of cervical carcinoma after laparoscopic lymphadenectomy. <i>Obstetrics and Gynecology</i> , 1997, 89, 864.	2.4	37
102	Neutralization of Endogenous Vascular Endothelial Growth Factor Depletes Primordial Follicles in the Mouse Ovary1. <i>Biology of Reproduction</i> , 2007, 76, 218-223.	2.7	37
103	The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2013, 128, 44-48.	1.4	37
104	Patterns of <i>CTCF</i> and <i>ZFX3</i> Mutation and Associated Outcomes in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv249.	6.3	37
105	Ultrasound mediated destruction of multifunctional microbubbles for image guided delivery of oxygen and drugs. <i>Ultrasonics Sonochemistry</i> , 2016, 28, 31-38.	8.2	37
106	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2010, 119, 531-537.	1.4	36
107	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. <i>Gastroenterology</i> , 2016, 151, 440-447.e1.	1.3	36
108	Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. <i>Gynecologic Oncology</i> , 2014, 133, 43-47.	1.4	35

#	ARTICLE	IF	CITATIONS
109	Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. <i>Cancer</i> , 2019, 125, 398-405.	4.1	35
110	Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. <i>Gynecologic Oncology</i> , 2015, 136, 300-304.	1.4	34
111	Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. <i>Oncoscience</i> , 2014, 1, 216-228.	2.2	33
112	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	32
113	Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?. <i>Gynecologic Oncology</i> , 2003, 91, 547-551.	1.4	31
114	Cost-Effectiveness Analysis of Strategies for the Surgical Management of Grade 1 Endometrial Adenocarcinoma. <i>Obstetrics and Gynecology</i> , 2007, 109, 1388-1395.	2.4	31
115	Lynch Syndrome. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 199-214.	1.1	31
116	Immunization with synthetic VEGF peptides in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 564-570.	1.4	30
117	High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. <i>PLoS ONE</i> , 2017, 12, e0170318.	2.5	30
118	Surgical pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?. <i>Gynecologic Oncology</i> , 2004, 94, 249-255.	1.4	29
119	Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. <i>Gynecologic Oncology</i> , 2013, 128, 113-119.	1.4	29
120	Noncatalytic <i>PTEN</i> missense mutation predisposes to organ-selective cancer development in vivo. <i>Genes and Development</i> , 2015, 29, 1707-1720.	5.9	29
121	Neuroendocrine carcinoma of the uterine cervix: The role of multimodality therapy in early-stage disease. <i>Gynecologic Oncology</i> , 2013, 129, 135-139.	1.4	28
122	High Frequency Strand Slippage Mutations in <i>CTCF</i> in MSI-Positive Endometrial Cancers. <i>Human Mutation</i> , 2014, 35, 63-65.	2.5	28
123	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw251.	6.3	28
124	Absence of <i>PTEN</i> Repeat Tract Mutation in Endometrial Cancers with Microsatellite Instability. <i>Gynecologic Oncology</i> , 2000, 79, 101-106.	1.4	27
125	Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: Time to change back?. <i>Gynecologic Oncology</i> , 2013, 128, 60-64.	1.4	27
126	Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2019, 152, 316-321.	1.4	27



#	ARTICLE	IF	CITATIONS
127	Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1717-1721.	2.5	26
128	Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1361-1371.	2.5	26
129	Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 957-967.	2.8	26
130	Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries. <i>Cancer</i> , 2020, 126, 1217-1224.	4.1	26
131	Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 631-634.	1.4	25
132	Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?. <i>Gynecologic Oncology</i> , 2014, 135, 95-99.	1.4	25
133	Is bariatric surgery an option for women with gynecologic cancer? Examining weight loss counseling practices and training among gynecologic oncology providers. <i>Gynecologic Oncology</i> , 2014, 134, 540-545.	1.4	25
134	Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma. <i>International Journal of Cancer</i> , 2017, 141, 1856-1866.	5.1	25
135	Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. <i>Cancer</i> , 2017, 123, 4004-4012.	4.1	25
136	Factors Predicting Subcutaneous Implanted Central Venous Port Function: The Relationship between Catheter Tip Location and Port Failure in Patients with Gynecologic Malignancies. <i>Gynecologic Oncology</i> , 2001, 83, 533-536.	1.4	24
137	Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 279-283.	1.4	24
138	Associations of long-chain n-3 fatty acids and fish intake with endometrial cancer risk in the Vitamins And Lifestyle cohort. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 599-608.	4.7	24
139	A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 136, 293-299.	1.4	24
140	The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment. <i>Gynecologic Oncology</i> , 2019, 153, 505-510.	1.4	24
141	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	1.4	24
142	Mesothelial Pelvic Lymph Node Inclusions Mimicking Metastatic Thyroid Carcinoma. <i>Gynecologic Oncology</i> , 1998, 68, 210-213.	1.4	23
143	Pre-emptive analgesia in gynecologic surgical procedures: Preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incision. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 901-905.	1.3	23
144	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	2.5	23

#	ARTICLE	IF	CITATIONS
145	Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. <i>Gynecologic Oncology</i> , 2015, 139, 70-76.	1.4	23
146	Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. <i>Materials Science and Engineering C</i> , 2019, 102, 113-123.	7.3	23
147	New Innovations in Cervical Cancer Screening. <i>Clinical Obstetrics and Gynecology</i> , 2001, 44, 538-549.	1.1	22
148	Stage IV endometrial cancer after failed conservative management: A case report. <i>Gynecologic Oncology</i> , 2008, 111, 579-582.	1.4	22
149	Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. <i>Gynecologic Oncology</i> , 2014, 135, 90-94.	1.4	22
150	Meigs? syndrome with an elevated CA 125 from benign Brenner tumors. <i>Obstetrics and Gynecology</i> , 2001, 98, 980-982.	2.4	21
151	Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. <i>Gynecologic Oncology</i> , 2009, 112, 146-149.	1.4	21
152	Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. <i>Translational Research</i> , 2013, 161, 156-164.	5.0	21
153	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	1.4	21
154	Gynecologic malignancies in adolescents. <i>Adolescent Medicine Clinics</i> , 2004, 15, 549-568.	0.8	20
155	Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. <i>Journal of Ovarian Research</i> , 2013, 6, 35.	3.0	20
156	Reducing readmissions after robotic surgical management of endometrial cancer: A potential for improved quality care. <i>Gynecologic Oncology</i> , 2013, 131, 508-511.	1.4	20
157	Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor. <i>Gynecologic Oncology</i> , 2014, 135, 133-141.	1.4	20
158	Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). <i>Gynecologic Oncology</i> , 2015, 139, 221-227.	1.4	20
159	Outpatient desensitization in selected patients with platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2017, 145, 603-610.	1.4	20
160	Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 295-301.	2.8	18
161	Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy. <i>Cancer</i> , 2004, 101, 106-115.	4.1	18
162	The Mucin Expression Profile of Endometrial Carcinoma and Correlation With Clinical-Pathologic Parameters. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 426-431.	1.2	18

#	ARTICLE	IF	CITATIONS
163	Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1271-1276.	2.5	18
164	<i>STAT3/PIAS3</i> Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. <i>Cancer Research</i> , 2018, 78, 1739-1750.	0.9	18
165	Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e92.	2.2	18
166	Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. <i>Gynecologic Oncology</i> , 2005, 98, 158-160.	1.4	17
167	Local correction of extreme stomal prolapse following transverse loop colostomy. <i>Gynecologic Oncology</i> , 2008, 111, 549-551.	1.4	17
168	Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin+cisplatin followed by whole abdomen irradiation. <i>Gynecologic Oncology</i> , 2009, 112, 553-557.	1.4	17
169	Long-chain n-3 fatty acid intake and endometrial cancer risk in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 824-834.	4.7	17
170	A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 429-434.	0.6	17
171	Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2003, 91, 134-138.	1.4	16
172	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer: A Phase 1 Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 682-686.	2.5	16
173	A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 262-266.	1.4	16
174	WWP2 and its association with PTEN in endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 13, 26-29.	0.6	16
175	Gestational trophoblastic diseases: new standards for therapy. <i>Current Opinion in Oncology</i> , 2000, 12, 492-496.	2.4	15
176	Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour) of Topotecan in Recurrent Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1331-1336.	2.5	15
177	Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 1107-1115.	3.4	15
178	Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 438-445.	2.5	15
179	Novel <i>SOX17</i> frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. <i>Oncotarget</i> , 2017, 8, 68758-68768.	1.8	15
180	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. <i>JCO Precision Oncology</i> , 2021, 5, 1588-1602.	3.0	15

#	ARTICLE	IF	CITATIONS
181	Robotic hysterectomy and lymphadenectomy for endometrial cancer: technical aspects and details of successâ€”the Ohio State University method. <i>Journal of Robotic Surgery</i> , 2008, 2, 71-76.	1.8	14
182	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. <i>Familial Cancer</i> , 2009, 8, 483-487.	1.9	14
183	The Use of Transvaginal Ultrasound in Type II Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 858-862.	2.5	14
184	Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer â€” An intriguing option in a population at risk for dying of complications of metabolic syndrome. <i>Gynecologic Oncology</i> , 2015, 138, 597-602.	1.4	14
185	Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 542-553.	7.0	14
186	Adenocarcinoma of the uterine cervix metastatic to lymph nodes. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 178, 1131-1137.	1.3	13
187	CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2008, 111, 233-236.	1.4	13
188	A Mindfulness-Based Lifestyle Intervention for Obese, Inactive Endometrial Cancer Survivors: A Feasibility Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 263-275.	2.0	13
189	Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?. <i>Gynecologic Oncology</i> , 2017, 144, 290-293.	1.4	13
190	A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 791-802.	2.8	12
191	Robotic Pelvic and Aortic Lymphadenectomy for Endometrial Cancer: The Console Surgeon's Perspectives on Surgical Technique and Directing the Assistant. <i>Journal of Minimally Invasive Gynecology</i> , 2010, 17, 180-185.	0.6	12
192	Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013, 128, 175-180.	1.4	12
193	Receipt of adjuvant endometrial cancer treatment according to race: anÂNRG Oncology/Gynecologic Oncology Group 210 Study. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 459.e1-459.e11.	1.3	12
194	The prognostic significance of the triple negative phenotype in endometrial cancer. <i>Gynecologic Oncology</i> , 2010, 118, 172-175.	1.4	11
195	Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: An early glimpse into a challenging initiative. <i>Gynecologic Oncology</i> , 2013, 130, 403-406.	1.4	11
196	The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: Insights from the US and Korean healthcare systems. <i>Gynecologic Oncology</i> , 2014, 135, 518-524.	1.4	11
197	Cardiovascular disease mortality among women with endometrial cancer in the Iowa Womenâ€™s Health Study. <i>Cancer Causes and Control</i> , 2017, 28, 1043-1051.	1.8	11
198	Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e120-e129.	2.5	11

#	ARTICLE	IF	CITATIONS
199	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectrum, 2020, 4, pkz075.	2.9	11
200	Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2021, 162, 626-630.	1.4	11
201	The Significance of Pneumatosis Intestinalis or Bowel Perforation in Patients with Gynecologic Malignancies. Gynecologic Oncology, 2002, 86, 79-84.	1.4	10
202	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
203	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. Journal of Oncology Practice, 2017, 13, e1030-e1039.	2.5	10
204	Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. Gynecologic Oncology, 2019, 153, 255-258.	1.4	10
205	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International Journal of Gynecological Cancer, 2020, 30, 1569-1575.	2.5	10
206	Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?. Gynecologic Oncology, 2012, 127, 362-366.	1.4	9
207	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecologic Oncology, 2015, 138, 689-693.	1.4	9
208	Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI. Gynecologic Oncology, 2016, 140, 405-408.	1.4	9
209	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. Journal of the National Cancer Institute, 2018, 110, 517-526.	6.3	9
210	Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival. Gynecologic Oncology, 2018, 150, 38-43.	1.4	9
211	Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study. International Journal of Cancer, 2020, 147, 404-412.	5.1	9
212	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. Gynecologic Oncology, 2020, 158, 194-200.	1.4	9
213	Outpatient Platinum-Taxane Intraperitoneal Chemotherapy Regimen for Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1195-1198.	2.5	9
214	Atypical Clustering of Gynecologic Malignancies: A Family Study Including Molecular Analysis of Candidate Genes. Gynecologic Oncology, 2000, 77, 18-25.	1.4	8
215	Consistency of In Vitro Chemoresponse Assay Results and Population Clinical Response Rates Among Women With Endometrial Carcinoma. International Journal of Gynecological Cancer, 2011, 21, 494-499.	2.5	8
216	Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and US perspectives. Gynecologic Oncology, 2016, 140, 83-89.	1.4	8

#	ARTICLE	IF	CITATIONS
217	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	1.4	8
218	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020, 156, 131-139.	1.4	8
219	Pathologic findings at risk-reducing salpingo-oophorectomy among women at increased ovarian cancer risk: Results from GOG-199. <i>Journal of Clinical Oncology</i> , 2012, 30, 1519-1519.	1.6	8
220	More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 244.e1-244.e17.	1.3	8
221	Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 104, 491-493.	1.4	7
222	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 833-838.	2.5	7
223	Predicting Inpatient Stay Lasting 2 Midnights or Longer After Robotic Surgery for Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 583-589.	0.6	7
224	Primum non nocere : Are we ready for POLE testing in endometrial cancer?. <i>Gynecologic Oncology</i> , 2017, 147, 240-242.	1.4	7
225	Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 4-5.	1.4	7
226	Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. <i>Neoplasia</i> , 2020, 22, 484-496.	5.3	7
227	Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?. <i>Oncologist</i> , 2021, 26, 1044-1051.	3.7	7
228	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 619-625.	1.4	7
229	Abstract 2594: Reovirus replication in ovarian and peritoneal tumors after intravenous administration. <i>Cancer Research</i> , 2010, 70, 2594-2594.	0.9	7
230	Temporary Extracorporeal Circulatory Support and Pulmonary Embolectomy for Catastrophic Amniotic Fluid Embolism. <i>Heart Surgery Forum</i> , 2011, 14, 157.	0.5	7
231	Ureteroileoneocystostomy: The Use of an Ileal Segment for Ureteral Substitution in Gynecologic Oncology. <i>Gynecologic Oncology</i> , 2002, 84, 110-114.	1.4	6
232	Advanced endometrial cancer with serous metastasis in a 17-year-old. <i>Gynecologic Oncology</i> , 2006, 101, 356-359.	1.4	6
233	Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2008, 108, 449-451.	1.4	6
234	Metastatic Squamous Cell Carcinoma of the Vulva to the Lung Confirmed With Allelotyping. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 497-501.	1.4	6

#	ARTICLE	IF	CITATIONS
235	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.	2.5	6
236	Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. <i>Gynecologic Oncology</i> , 2016, 143, 484-489.	1.4	6
237	Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 35-42.	2.5	6
238	Reproductive counseling, contraception, and unplanned pregnancy in fertile women treated by gynecologic oncologists. <i>Gynecologic Oncology Reports</i> , 2017, 19, 22-26.	0.6	6
239	Functional characterization of recurrent <i>FOXA2</i> mutations seen in endometrial cancers. <i>International Journal of Cancer</i> , 2018, 143, 2955-2961.	5.1	6
240	Inherited alterations of TGF beta signaling components in Appalachian cervical cancers. <i>Cancer Causes and Control</i> , 2019, 30, 1087-1100.	1.8	6
241	Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2022, 165, 500-505.	1.4	6
242	Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 338-342.	1.4	5
243	Options for repair of rectus abdominis myocutaneous perineal/vaginal flap prolapse: A case series. <i>Gynecologic Oncology Case Reports</i> , 2014, 7, 1-3.	0.9	5
244	Aspirin and endometrial cancer risk. <i>Gynecologic Oncology Reports</i> , 2016, 17, 1-2.	0.6	5
245	Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons Learned. <i>Journal of Cancer Education</i> , 2018, 33, 857-864.	1.3	5
246	The association between histological subtype of a first primary endometrial cancer and second cancer risk. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 290-298.	2.5	5
247	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. <i>Gynecologic Oncology</i> , 2020, 158, 201-207.	1.4	5
248	No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. <i>Human Mutation</i> , 2001, 17, 117-121.	2.5	4
249	Surgery or chemoradiation for stage IB cervical cancer? How cost effectiveness impacts a complex decision. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 79.	2.2	4
250	The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?. <i>Gynecologic Oncology Reports</i> , 2015, 13, 47-48.	0.6	4
251	The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2017, 145, 185-191.	1.4	4
252	Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy. <i>Gynecologic Oncology</i> , 2022, 164, 628-638.	1.4	4

#	ARTICLE	IF	CITATIONS
253	Comprehensive evaluation of caspase-14 in vulvar neoplasia: An opportunity for treatment with black raspberry extract. <i>Gynecologic Oncology</i> , 2014, 135, 503-509.	1.4	3
254	Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. <i>Gynecologic Oncology</i> , 2015, 138, 712-716.	1.4	3
255	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 660-661.	0.4	3
256	Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 21-25.	1.7	3
257	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 445-451.	1.4	3
258	Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. <i>Gynecologic Oncology</i> , 2020, 156, 701-709.	1.4	3
259	Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound. <i>Gynecologic Oncology</i> , 2021, , .	1.4	3
260	Role of lymphadenectomy in the staging of endometrial cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 382-384.	27.6	2
261	Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. <i>Gynecologic Oncology</i> , 2017, 144, 451-455.	1.4	2
262	Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?. <i>Gynecologic Oncology</i> , 2017, 145, 1-2.	1.4	2
263	Cancer care delivery research in gynecologic oncology. <i>Gynecologic Oncology</i> , 2018, 148, 445-448.	1.4	2
264	Role of Minimally Invasive Surgery in Gynecologic Malignancies. , 2012, , 631-649.e9.		1
265	Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 336-337.	0.4	1
266	Role of Minimally Invasive Surgery in Gynecologic Malignancies. , 2018, , 560-578.e11.		1
267	Wound complications following vulvar excision for nonmalignant lesions. <i>AJOG Global Reports</i> , 2021, 1, 100022.	1.0	1
268	Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy. <i>Gynecologic Oncology</i> , 2022, 166, 69-75.	1.4	1
269	Cost-Effectiveness Analysis of Strategies for the Surgical Management of Grade 1 Endometrial Adenocarcinoma. <i>Obstetrics and Gynecology</i> , 2007, 110, 933-934.	2.4	0
270	RE: Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2008, 110, 269.	1.4	0



#	ARTICLE	IF	CITATIONS
271	Corrigendum to "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer" [Gynecologic Oncology 111 (2008) 461-466]. Gynecologic Oncology, 2010, 119, 603.	1.4	0
272	What does cost have to do with it?. Gynecologic Oncology, 2011, 122, 465-466.	1.4	0
273	Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218). Obstetrical and Gynecological Survey, 2016, 71, 24-26.	0.4	0
274	Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?. Gynecologic Oncology, 2020, 157, 706-710.	1.4	0
275	Vaginal Reconstruction in Pelvic Exenteration. , 2004, , 663-673.		0
276	Ovarian and Endometrial Cancer in Patients with Hereditary Non-polyposis Colorectal Cancer Syndrome. , 2009, , 163-181.		0
277	Minimally invasive surgery. , 2010, , 235-249.		0
278	Neuroendocrine carcinoma of the cervix: A single institution's experience.. Journal of Clinical Oncology, 2012, 30, e15585-e15585.	1.6	0
279	Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.. Journal of Clinical Oncology, 2012, 30, 5101-5101.	1.6	0
280	Evaluation of the hematologic safety of same day versus standard administration of pegfilgrastim in gynecology oncology patients undergoing platinum-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 5569-5569.	1.6	0